This Viewpoint discusses the initials results of the NCI-MATCH trial, a phase 2 study that seeks to determine whether targeted therapies for specific gene mutations will lead to objective responses agnostic to the primary cancer type.
https://ift.tt/2qzDthl
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου